IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
Status:
Completed
Trial end date:
2019-12-20
Target enrollment:
Participant gender:
Summary
This study is being carried out in order to evaluate a new cancer vaccine called IMA970A
combined with CV8102, a new adjuvant for the treatment of liver cancer (hepatocellular
carcinoma). It will be investigated whether IMA970A and CV8102 is safe and can trigger an
immune response against the tumor, which may prevent the tumor (cancer) from recurring or
spreading or may even lead to tumor shrinkage following the standard treatments the patients
have previously received.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Cancer Institute, Naples
Collaborators:
CureVac AG European Commission -FP7-Health-2013-Innovation-1 immatics Biotechnologies GmbH